Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial

COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in no...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Circulation (New York, N.Y.) Ročník 147; číslo 25; s. 1891
Hlavní autoři:	Piazza, Gregory, Spyropoulos, Alex C, Hsia, Judith, Goldin, Mark, Towner, William J, Go, Alan S, Bull, Todd M, Weng, Stephen, Lipardi, Concetta, Barnathan, Elliot S, Bonaca, Marc P
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 20.06.2023
Témata:	Anticoagulants - adverse effects COVID-19 Hemorrhage - chemically induced Hemorrhage - drug therapy Hospitalization Humans Outpatients Rivaroxaban - adverse effects Thrombosis - epidemiology Thrombosis - prevention & control COVID-19 pre-exposure prophylaxis prevention and control rivaroxaban thrombosis venous thromboembolism
ISSN:	1524-4539, 1524-4539
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!